Tessera Therapeutics is pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. Tessera’s Gene Writers are delivered as therapeutic compositions comprised of RNA molecules within lipid nanoparticles, offering the potential for scalable, re-dosable genetic medicines with the ability to make the full spectrum of small and large edits to genome, from single or multi-base pair corrections, insertions, deletions, to writing entire genes. Gene Writing requires a DNA sequence match at all three steps, reducing the likelihood of off-target editing. TPRT uses three steps to make an alteration: DNA-binding, DNA-nicking (without double strand breaks to DNA), and reverse transcription. Tessera’s lead Gene Writers for the collaboration with the Cystic Fibrosis Foundation use target-primed reverse transcription (TPRT), which evolved in a class of MGEs known as retrotransposons. These candidates are run through Tessera’s research engine to optimize them for efficiency, specificity, and fidelity-essentially compressing eons of evolution into a few months. Tessera has evaluated tens of thousands of natural and synthetic MGEs to create candidate Gene Writers with the ability to write therapeutic messages into the human genome. Tessera’s Gene Writers are based on nature’s genome architects, Mobile Genetic Elements (MGEs)-the most abundant class of genes across the tree of life, representing approximately half of the human genome. “Gene Writers have the potential to revolutionize the treatment of cystic fibrosis and to deliver multiple new medicines that introduce a full length CFTR sequence, or to make true corrections of pathogenic alleles in the CFTR sequence.” “The collaboration of Pioneering Medicines and the Cystic Fibrosis Foundation will support development of Gene Writers designed to give people living with cystic fibrosis functional CFTR genes, with the goal of restoring normal, healthy lung function,” said Paul Biondi, President, Pioneering Medicines and Executive Partner, Flagship Pioneering. Tessera and Pioneering Medicines-an initiative that brings together complementary technologies from Flagship Pioneering’s portfolio of companies-will advance the technology through preclinical development and prepare it for first-in-human proof of concept studies. This includes the ability to make true corrections of specific mutations, such as the F508-del mutation, which drives roughly 70% of CF cases, as well as other nonsense mutations, and to introduce a functional full-length copy of the CFTR gene at its endogenous locus. The agreement involves multiple Gene Writers in Tessera’s portfolio of candidates and applies them to cystic fibrosis. We hope our collaboration leads to treatments and cures for cystic fibrosis.” “The Cystic Fibrosis Foundation’s extensive network of scientists, companies, and clinicians knowledgeable about cystic fibrosis will help accelerate screening and development of our cystic fibrosis-targeting Gene Writers. “We’re excited to work with the Cystic Fibrosis Foundation, the world’s leader in supporting breakthrough technologies for cystic fibrosis,” said Geoffrey von Maltzahn, Ph.D, Co-Founder and CEO of Tessera, and General Partner at Flagship Pioneering. Furthermore, current treatments are ineffective for about 10% of individuals living with cystic fibrosis. While major advances have been made over the past decade that have led to more therapeutic options for individuals living with cystic fibrosis, a curative approach is still lacking. It affects approximately 70 thousand people globally. Cystic fibrosis is an inherited genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that cause persistent and worsening lung congestion and infections that limit a person’s ability to breathe. Gene Writers make precise single nucleotide changes, small insertions and deletions, and can replace entire genes in a programmable way to correct the genetic code driving disease. The Gene Writers are part of a portfolio of technologies that Pioneering Medicines has assembled to treat cystic fibrosis as part of a broader collaboration with the Cystic Fibrosis Foundation. Tessera Therapeutics today announced a treatment-focused collaboration with the Cystic Fibrosis Foundation using Tessera’s Gene Writing technology to rewrite the genetic codes that cause cystic fibrosis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |